Robert Figlin, MD, is interim director of Cedars-Sinai Cancer and interim director of the Samuel Oschin Comprehensive Cancer Institute, and holds the Steven Spielberg Family Chair in Hematology Oncology.
He is a professor of medicine and biomedical sciences at Cedars-Sinai and an emeritus professor of medicine and urology at the David Geffen School of Medicine at UCLA. A nationally recognized leader in genitourinary and thoracic oncology, Dr. Figlin focuses his research on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at Cedars-Sinai, which works to understand the biology of kidney cancer and translate that knowledge into novel, less toxic treatment approaches.
Before joining Cedars-Sinai, he held the Arthur and Rosalie Kaplan Endowed Chair of the Department of Medical Oncology and Therapeutics Research and served as associate director for clinical research at the City of Hope Comprehensive Cancer Center.
Earlier, at UCLA, he was the Henry Alvin and Carrie L. Meinhardt Endowed Chair in Urologic Oncology and co-director of the Jonsson Comprehensive Cancer Center’s oncology program. Dr. Figlin serves as editor of the Kidney Cancer Journal, and his work has appeared in the Journal of Clinical Oncology, The New England Journal of Medicine, and The Lancet, among others. He has authored more than 400 peer-reviewed articles and over 70 book chapters and has served as editor of multiple books on kidney cancer.
He received his medical degree from the Medical College of Pennsylvania, completed his residency and chief residency in internal medicine at Cedars-Sinai Medical Center, and completed a fellowship in hematology/oncology at the David Geffen School of Medicine at UCLA.